ArticleClinical and translational medicine2026
M6A demethylase ALKBH5 mediated Igfbp4 mRNA m6A modification drives fibroblast activation and pathological upper airway fibrosis.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLaryngotracheal stenosis (LTS) is a fibroproliferative disease of the upper airway characterised by dysregulated extracellular matrix deposition and fibroblast activation. AlkB Homologue 5 (ALKBH5) has emerged as a key regulator of disease pathogenesis by modulating mRNA stability, yet its role in LTS remains unclear.
methodsWe established a LTS rat model and observed mRNA m6A methylation and m6A demethylase ALKBH5 in stenotic tissues. Using single-cell RNA sequencing, in vivo ALKBH5 knockout models, and in vitro gain- and loss-of-function assays, we explored the role of ALKBH5 in fibroblast activation and fibrosis. The downstream target of ALKBH5 and its underlying molecular mechanism were identified through integrating RNA-seq and MeRIP-seq analyses, and further validated by RNA immunoprecipitation (RIP)-quantitative PCR (qPCR), dual-luciferase reporter assays, and in vitro gain- and loss-of-function experiments. In addition, the therapeutic potential of exogenous modulation of ALKBH5 target was evaluated in LTS models.
resultsALKBH5 acted as a key pro-fibrotic regulator by enhancing the expression of COL1A1, COL3A1 and alpha-smooth muscle actin (α-SMA), increasing fibroblast contractility, and promoting airway fibrosis progression in LTS. RNA-seq and MeRIP-seq analyses identified Igfbp4 as a direct target of ALKBH5. RIP-qPCR and luciferase reporter assay confirmed ALKBH5 binding to the 3'-untranslated region of Igfbp4. Functional studies revealed that IGFBP4 inhibited β-catenin signalling and attenuated fibroblast activation. Overexpression of IGFBP4 partly reversed the profibrotic effects of ALKBH5, both in vitro and in vivo, significantly reducing collagen deposition and airway narrowing in LTS rats.
conclusionOur findings identify a novel ALKBH5-IGFBP4 regulatory axis that drives fibroblast activation and airway fibrosis in LTS. Targeting ALKBH5 or supplementing IGFBP4 may become novel therapeutic strategies for LTS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.